Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212

Next Previous
X
Search
Trial Profile

A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selurampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions
  • Sponsors Novartis

    • Most Recent Events

    • 11 Apr 2016 Trial protocol (Primary endpoints,time frame for primary endpoints and treatment ) amended.
    • 06 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials. gov.
    • 06 Jan 2015 Planned End Date changed from 1 Nov 2014 to 1 Jun 2015, according to ClinicalTrials. gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top